Advanced Enzyme Technologies Shows Strong Q1-FY26 Performance with 24% EBITDA Growth

Advanced Enzyme Technologies (ADVENZY) reported an 11% quarter-on-quarter revenue increase and a 24% surge in EBITDA for Q1-FY26, signaling a robust start to the fiscal year. The Human Nutrition segment, particularly the Serratiopeptidase (Sera) product, drove growth with a 49% year-on-year expansion, bolstered by strategic pricing and strong contributions from IPCA.

EBITDA margins improved by 308 basis points, attributed to operational leverage. The company anticipates sustained growth in FY26, supported by its market leadership in Sera, a recovering nutraceuticals business overseas, and a strengthened animal nutrition portfolio.

Capacity expansions at JC Biotech and SSPL, alongside a new R&D lab, are expected to enhance medium-term growth. With current capacity utilization at 65%, potential brownfield expansions could further boost revenues from FY28 onward.